The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer.
暂无分享,去创建一个
[1] J. Matthews,et al. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. , 2002, International journal of radiation oncology, biology, physics.
[2] V Grégoire,et al. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). , 2011, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[3] Curtis B Caldwell,et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. , 2002, International journal of radiation oncology, biology, physics.
[4] Sasa Mutic,et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] B. Murray,et al. Thresholding in PET images of static and moving targets , 2005, Physics in medicine and biology.
[6] Rodney J Hicks,et al. Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. , 2007, International journal of radiation oncology, biology, physics.
[7] A. Maier,et al. Resection in stage I/II non-small cell lung cancer. , 2010, Frontiers of radiation therapy and oncology.
[8] M. M. Mac Manus,et al. How can we tell if PET imaging for cancer is cost effective? , 2010, The Lancet. Oncology.
[9] K Schnabel,et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. , 1999, International journal of radiation oncology, biology, physics.
[10] C. Rübe,et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] Philippe Lambin,et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. , 2007, International journal of radiation oncology, biology, physics.
[12] Anil Sethi,et al. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning. , 2007, International journal of radiation oncology, biology, physics.
[13] Robert Jeraj,et al. PET scans in radiotherapy planning of lung cancer. , 2012, Lung cancer.
[14] Michalis Aristophanous,et al. Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning. , 2012, International journal of radiation oncology, biology, physics.
[15] P. Lambin,et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] Ursula Nestle,et al. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[17] C B Caldwell,et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. , 2001, International journal of radiation oncology, biology, physics.
[18] Sasa Mutic,et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.
[19] Y. Ung,et al. Positron Emission Tomography in Staging Early Lung Cancer , 2009, Annals of Internal Medicine.
[20] M. Boers,et al. Toward less futile surgery in non-small cell lung cancer? A randomized clinical trial to evaluate the cost-effectiveness of positron emission tomography. , 2001, Controlled clinical trials.
[21] Tomas Kron,et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. , 2009, International journal of radiation oncology, biology, physics.
[22] Douglas C McCrory,et al. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. , 2003, Chest.
[23] Hak Choy,et al. A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. , 2009, International journal of radiation oncology, biology, physics.
[24] Sung-Cheng Huang,et al. Anatomy of SUV , 2000 .
[25] D. Owens,et al. Test Performance of Positron Emission Tomography and Computed Tomography for Mediastinal Staging in Patients with NonSmall-Cell Lung Cancer , 2003, Annals of Internal Medicine.
[26] V Kalff,et al. F‐18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma , 2001, Cancer.
[27] D. Mankoff,et al. 18F-Fluorothymidine radiation dosimetry in human PET imaging studies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] T G Turkington,et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. , 1999, Lung cancer.
[29] P. Lambin,et al. High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[30] Slobodan Devic,et al. Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. , 2008, International journal of radiation oncology, biology, physics.
[31] John J. Crowley,et al. 国际肺癌研究会分期项目——采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[32] R. Bares,et al. FDG PET for staging of advanced non-small cell lung cancer prior to neoadjuvant radio-chemotherapy , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[33] H. Groen,et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] U. Nestle,et al. FDG-PET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning--an intraindividual comparison. , 2009, International journal of radiation oncology, biology, physics.
[35] J. Crowley,et al. We probably have the answer: now what is the question? , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[36] J. Verschakelen,et al. Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer , 2007, European Respiratory Journal.
[37] E. Touboul,et al. Impact of (18)F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: A prospective multicenter study. , 2010, AJR. American journal of roentgenology.
[38] V Kalff,et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Morelle,et al. Assessing short-term effects and costs at an early stage of innovation: The use of positron emission tomography on radiotherapy treatment decision making , 2008, International Journal of Technology Assessment in Health Care.
[41] Sadek Nehmeh,et al. Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? , 2005, International journal of radiation oncology, biology, physics.
[42] R. Fisher,et al. Measurement of lung tumor volumes using three-dimensional computer planning software. , 2002, International journal of radiation oncology, biology, physics.
[43] Gerald J. Kutcher,et al. The impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer , 2000 .
[44] T. Ackerly,et al. Display of positron emission tomography with Cadplan , 2002, Australasian Physics & Engineering Sciences in Medicine.
[45] D K Owens,et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.
[46] Ludy Lutgens,et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. , 2005, International journal of radiation oncology, biology, physics.
[47] Arjan Bel,et al. Definition of gross tumor volume in lung cancer: inter-observer variability. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[48] G. V. von Schulthess,et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.
[49] Wolfgang Enghardt,et al. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning? , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[50] Ursula Nestle,et al. Biological imaging in radiation therapy: role of positron emission tomography , 2009, Physics in medicine and biology.
[51] T. Naruke,et al. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. , 2005, The Annals of thoracic surgery.
[52] J. Mortensen,et al. Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[53] L. H. Gray,et al. Influence of oxygen tension on x-ray-induced chromosomal damage in Ehrlich ascites tumor cells irradiated in vitro and in vivo. , 1959, Radiation research.
[54] Indrin J Chetty,et al. A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Tomio Inoue,et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[56] M. Schneider-Kolsky,et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose‐positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer , 2010, Cancer.
[57] S. Nehmeh,et al. An iterative technique to segment PET lesions using a Monte Carlo based mathematical model. , 2009, Medical physics.
[58] V. Rusch,et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.
[59] A. Hogg,et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. , 2001, International journal of radiation oncology, biology, physics.
[60] Hanna El Balaa,et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. , 2005, International journal of radiation oncology, biology, physics.
[61] K. Bujko,et al. Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study. , 2011, International journal of radiation oncology, biology, physics.
[62] M. Yaffe,et al. Developing a methodology for three-dimensional correlation of PET–CT images and whole-mount histopathology in non-small-cell lung cancer , 2008, Current oncology.
[63] P. Marsden,et al. Recommendations for the use of PET and PET-CT for radiotherapy planning in research projects. , 2012, The British journal of radiology.
[64] Joe Y. Chang,et al. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer , 2009, Radiation oncology.
[65] Target Volume Definition , 2009 .
[66] Philippe Lambin,et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.